Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.

Fiche publication

Date publication

septembre 2022

Journal

British journal of clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROYER Bernard , Pr SCHMITT Antonin

Tous les auteurs :
Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, Tron C, Le Louedec F, Ciccolini J, Richard D, Alarcan H, Haufroid V, Tafzi N, Schmitt A, Etienne-Grimaldi MC, Narjoz C, Thomas F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36104927

Résumé

Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidines (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH ) concentrations, since they are essential in reliable DPD deficiency testing.